SAN DIEGO--(BUSINESS WIRE)--Biolinq Incorporated, a medtech company that is developing novel biosensing technologies, has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd., to commercialize a new generation of glucose monitoring products in Japan.
JUPITER, FL / ACCESSWIRE / August 16, 2022 / Jupiter Wellness, Inc. (NASDAQ:JUPW) today announced financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights.
JUPITER, FL / ACCESSWIRE / June 23, 2022 / Jupiter Wellness (NASDAQ:JUPW) and Taisho Pharmaceutical Co. Ltd (TYO:4581) today announced that Taisho Pharmaceutical has entered into a license agreement for Jupiter Wellness's minoxidil booster for the Japanese market.
BALTIMORE, March 7, 2022 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based platform biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, announced today that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd.
Ancora poached Sage Chief Medical Officer Stephen Kanes, M.D., Ph.D., as its chief executive. During his roughly eight-year tenure at Sage, Kanes led the clinical development of Zulresso, which snagged the first FDA approval for postpartum depression in March 2019.
Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol capsules 0.5 µg and 0.75 µg (hereafter, “Edirol”), a treatment for osteoporosis for which Chugai has a marketing authorization.
Taisho Pharmaceutical tapped artificial intelligence drug discovery maven Insilico Medicine to identify new therapeutic compounds that could slow the cellular effects of aging, with the ultimate goal of helping people stay healthy as they grow older.
HONG KONG, Oct. 15, 2020 /PRNewswire/ -- Insilico Medicine announced today that Taisho Pharmaceutical Co., Ltd. and Insilico have entered into a research collaboration to identify novel therapeutics against aging. Insilico Medicine will utilize both the target discovery and generative chemistry parts of its Pharma.AI platform in this collaboration. It will use its proprietary Pandomics Discovery Platform to identify novel targets for senolytic drugs and Chemistry42 platform for a molecular generation. This collaboration brings together Insilico's state-of-art artificial intelligence (AI) technologies in drug discovery with Taisho's expertise in drug development, aimed to extend the human healthspan.
RICHMOND, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and age-related diseases, today announced that it has entered into an exclusive worldwide license agreement with Taisho Pharmaceutical Co., Ltd. [Head Office: Toshima-ku, Tokyo, President: Shigeru Uehara] (“Taisho”) to develop and commercialize Taisho's clinical-stage Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, BGE-117 (named TS-143 by Taisho), to ameliorate multiple diseases of aging.
Moberg Pharma AB (OMX: MOB) has signed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd for development, registration and commercialization of MOB-015 in Japan. Under the agreement, Moberg Pharma is eligible to receive milestones of up to USD 50 million contingent on development and commercial success, as well as supply fees including royalties.